Komori
Disclosure4512WAKAMOTO PHARMACEUTICAL CO.,LTD.Pharmaceuticals

Notice Regarding the Recording of a Gain on Sale of Investment Securities (Extraordinary Income)

We plan to sell part of one listed security we hold and recognize a gain on the sale of ¥152 million as extraordinary income in the first quarter of the fiscal year ending March 2027.

Worth reading
61In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Improvement
Direction inferred from the company’s description.
Scale
152
¥ million
Wording
Conditional
How definitive the wording is.

Decision and Details

Recognition of Gain on Sale of Investment Securities (Extraordinary Income)

Period CoveredFirst quarter of the fiscal year ending March 2027
Implementation8 April 2026 (scheduled date of occurrence of the gain on sale of investment securities)
Going forwardThe gain on sale of investment securities is scheduled to arise on 8 April 2026 and will be recognized as extraordinary income in the financial results for the first quarter of the fiscal year ending March 2027.
AmountGain on sale of investment securities: ¥152 million
Quantity / scale1 listed security
Reason

To improve the efficiency of the Company’s asset holdings

Impact on Business Performance

We plan to recognize the ¥152 million gain on sale of investment securities as extraordinary income in the financial results for the first quarter of the fiscal year ending March 2027.

Decision and Details
ItemDetails
Matter CoveredRecognition of Gain on Sale of Investment Securities (Extraordinary Income)
Implementation Date8 April 2026 (scheduled date of occurrence of the gain on sale of investment securities)
Period CoveredFirst quarter of the fiscal year ending March 2027
AmountGain on sale of investment securities: ¥152 million
Quantity / scale1 listed security
Impact on Business PerformanceWe plan to recognize the ¥152 million gain on sale of investment securities as extraordinary income in the financial results for the first quarter of the fiscal year ending March 2027.
ReasonTo improve the efficiency of the Company’s asset holdings
Future plansThe gain on sale of investment securities is scheduled to arise on 8 April 2026 and will be recognized as extraordinary income in the financial results for the first quarter of the fiscal year ending March 2027.
Items this document does not state (4)
Decision-Making BodyDecision DateGoverning RuleRelated previous disclosures

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

To improve the efficiency of our asset holdings.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Regarding the Recording of a Gain on Sale of Investment Securities (Extraordinary Income) | WAKAMOTO PHARMACEUTICAL CO.,LTD. (4512) timely disclosure | Komori